Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

From genotype to phenotype: uncovering the cellular pathology of SRRM2 Gene mutations in neurodevelopmental disorders

EF 2025-26

Résumé
Every child deserves the chance to grow, learn, and thrive-but for many Canadian children with neurodevelopmental disorders, these opportunities are limited. These conditions disrupt the normal growth of the brain and spinal cord, causing lifelong challenges in learning, communication, and daily living. In Canada, 74% of children with disabilities are affected by these disorders (Miller, 2013), yet effective treatments remain rare. The challenge lies in the complex biology of these disorders and the overlap in symptoms, which makes them difficult to diagnose and treat. Recent research has identified SRRM2, a key protein inside our cells, as the cause of a newly recognized neurodevelopmental disorder. Children with a defective SRRM2 copy experience delayed speech, hindered growth, and reduced cognitive abilities. However, we do not yet understand how SRRM2 defects change its function inside cells, or how these changes lead to disease. Without this knowledge, targeted treatments cannot be developed. Our project will address this gap. Using advanced microscopy and light-based imaging, we will track SRRM2's exact location, movement, and interactions in living cells. We will use multiple approaches to identify readouts that we can use to search for compounds that restore normal SRRM2 function. By uncovering these readouts, we will open the door to new therapies, offering hope to Canadian children and families living with SRRM2-related disability and potentially benefiting those with other neurodevelopmental disorders that share similar pathways. Reference: Miller, A. R. et al. (2013). Disability and rehabilitation, 35(6), 468-478.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559647
Name
Elsakrmy Noha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
From genotype to phenotype: uncovering the cellular pathology of SRRM2 Gene mutations in neurodevelopmental disorders
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Intellectual Disability; Membraneless Organelles; Missense Mutations; Neurodevelopmental; Nuclear Speckles; Prime Editing; Rna; Spliceosome; Splicing; Tissue Culture
Abstract
Every child deserves the chance to grow, learn, and thrive-but for many Canadian children with neurodevelopmental disorders, these opportunities are limited. These conditions disrupt the normal growth of the brain and spinal cord, causing lifelong challenges in learning, communication, and daily living. In Canada, 74% of children with disabilities are affected by these disorders (Miller, 2013), yet effective treatments remain rare. The challenge lies in the complex biology of these disorders and the overlap in symptoms, which makes them difficult to diagnose and treat. Recent research has identified SRRM2, a key protein inside our cells, as the cause of a newly recognized neurodevelopmental disorder. Children with a defective SRRM2 copy experience delayed speech, hindered growth, and reduced cognitive abilities. However, we do not yet understand how SRRM2 defects change its function inside cells, or how these changes lead to disease. Without this knowledge, targeted treatments cannot be developed. Our project will address this gap. Using advanced microscopy and light-based imaging, we will track SRRM2's exact location, movement, and interactions in living cells. We will use multiple approaches to identify readouts that we can use to search for compounds that restore normal SRRM2 function. By uncovering these readouts, we will open the door to new therapies, offering hope to Canadian children and families living with SRRM2-related disability and potentially benefiting those with other neurodevelopmental disorders that share similar pathways. Reference: Miller, A. R. et al. (2013). Disability and rehabilitation, 35(6), 468-478.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Elsakrmy, Noha
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~